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The survival from bronchogenic carcinoma is highly dependent upon stage at the time of
treatment. This is particularly true for squamous cell carcinoma, adenocarcinoma, and large
cell carcinoma, but holds true for small cell carcinoma as well. The problem presented to the
medical profession has been to find a practical means ofdetecting lung cancer while it is still at
an early stage. Three studies in progress have indicated that a larger proportion ofthe patients
may be found to have early stage lung cancer when screened with a combination of chest
X-rays and sputum cytology. However, thedetection ofthese early stage cases has not yet been
translated into an improvement in the overall mortality rate from lung cancer.
PROBLEM
The incidence of lung cancer has continued to climb dramatically throughout the
last fifty years. In 1930, the incidence of lung cancer was approximately five per
100,000 men. In 1970 it was approximately 14 times as high with an incidence of 70
per 100,000. The American Cancer Society estimates that 122,000 people in this
country will get lung cancer in 1981 and that 105,000 ofthem will die ofthis disease.
Approximately one American will die oflung cancer every five minutes. The overall
five-year survival from lung cancer in men is 8 percent. In large part, this is due to
the fact that only 17 percent of lung cancers present clinically as localized disease.
The remainder of the patients have either regional or distant metastases at the time
of discovery [1].
The survival from bronchogenic carcinoma is highly dependent upon stage at the
time of treatment. The American Joint Commission has devised a TNM system for
bronchogenic carcinoma [2]. T stands for tumor, N for lymph node metastases, and
M for distant metastases. In Stage I disease (local disease) the five-year survival
from squamous cell carcinoma is approximately 38 percent, large cell carcinoma 31
percent, and adenocarcinoma 32 percent. In Stage II (regional) disease the five-year
survival for squamous cell carcinoma drops to 16 percent, for large cell undifferen-
tiated to 7 percent, and for adenocarcinoma to 8 percent. For Stage III disease
(tumor which has invaded from the lung into the thoracic contents, or which has
metastasized to the mediastinum or to distant viscera) the five-year survival for
squamous cell carcinoma is 10 percent, for large cell undifferentiated carcinoma 5
percent, and for adenocarcinoma 3 percent [2].
Even small cell carcinoma can be broken into groups on the basis of the apparent
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All rights of reproduction in any form reserved.extent of disease at the time of detection. In those patients with small cell carcinoma
apparently localized to the chest after careful staging, who have been treated with a
combination of radiotherapy and chemotherapy, there is a 50 percent complete
remission rate and a 20 percent survival at two-plus years [3,4]. For patients with
higher stage small cell carcinoma, there are only a few survivors at six months.
If the task is to reduce the mortality from cancer of the lung, there are only two
ways to go about it.
1. Prevention. This would be the most desirable method. A host of environmen-
tal carcinogens capable of producing bronchogenic carcinoma have been described
and continue to be identified. Perhaps the most important single factor in the in-
cidence oflung cancer is cigarette smoking. Efforts to remove the carcinogens from
the environment and stop people from smoking have obviously not been successful
in preventing a rapid increase in the incidence of this disease. The Surgeon General's
report in 1964 clearly pointed out the dangers ofcigarette smoking, but the mortality
from lung cancer 17 years later is 75 percent higher in men and 100 percent higher in
women [1].
2. Effective Treatment ofthe Disease. Numerous studies have been undertaken
in an attempt to find a modality of treatment which would be effective in high-stage
lung cancer. A variety of drugs and radiotherapic regimens have been used against
all the various subtypes of bronchogenic carcinoma. Even in small cell carcinoma,
the most responsive to radiation and to chemotherapy, there has been very limited
success with high-stage disease. With the other types of bronchogenic carcinoma,
the success achieved has been even less.
Treatment of low-stage disease, however, has been relatively successful. The
surgical treatment of squamous cell carcinoma, adenocarcinoma, and large cell un-
differentiated carcinoma leads to a cumulative five-year survival rate of over 50 per-
cent when these lesions are in Stage I at the time of treatment [2,5]. In an attempt to
increase the percentage ofbronchogenic carcinomas which are found as local disease
at the time of detection, a number ofscreening programs have been employed. The
various types ofbronchogenic carcinoma present different problems in the screening
process.
Squamous Cell Carcinoma
Squamous cell carcinoma begins in the basal layer of the bronchial epithelium of
bronchi which are usually ofsubsegmental order or larger. This type of brnchogenic
carcinoma, approximately 40 percent of lung cancers, passes through three stages:
(1) pre-carcinoma or dysplastic stage, (2) pre-clinical stage of squamous cell car-
cinoma, and (3) clinical stage of squamous cell ccarcinoma [6].
In thepre-carcinomaphase, the presence of a lesion can be detected only by find-
ing dysplastic cells in sputum. This has been done on relatively few occasions. Sac-
comanno [7] described the progression of changes from dysplasia to frank cancer.
The duration of this period is long, at least several years in the few reliable studies
which have been published.
Thepre-clinicalphase ofsquamous cell carcinoma begins with the detection in the
sputum of malignant squamous cells. At the first appearance of these cells, the pa-
tients are asymptomatic and the plain chest X-ray is not revealing. A number of
workers studying the rather unusual examples ofsquamous cell carcinomas resected
during this phase in their development have shown that there is a broad range in the
extent of tumor in this phase. It progresses from in-situ carcinoma in the surface
epithelium to in-situ carcinoma in the submucosal glandular epithelium to invasion
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of the bronchial wall and extension to hilar or even mediastinal lymph nodes before
signs or symptoms are produced. A number ofreports have indicated that squamous
cell carcinoma found in the pre-clinical phase has a high resectability and potential
curability rate [5]. There are problems related to the finding of tumors in this early
stage oftheir clinical course [8]. Careful localization with fiberoptic bronchoscopy is
required [9,10]. Extension of even very early squamous cell carcinoma to proximal
or lobar bronchial margins, the presence of multifocal disease appearing either syn-
chronously or subsequently, and the extent of underlying pulmonary disease in this
group of patients create problems for the surgeon attempting to treat such lesions
conservatively [11]. Nevertheless the results of treatment in this stage are among the
best achieved for bronchogenic carcinoma. In 89 patients reported by Melamed [12],
Pearson [13], Woolner [14], Lerner [15], Martini [16], Carter [11], and their respec-
tive associates, 81 percent underwent resection for cure and 76 percent were alive at
the time the cases were reported.
The signs and symptoms of the clinical stage of squamous cell carcinoma are pro-
duced by the growth of the primary tumor to produce obstruction ofthe bronchus in
which it arises. Most of the course of the disease has preceded the first clinical ap-
pearance of squamous cell carcinoma. Even at this stage, squamous cell carcinoma
may still be at Stage I by the American Joint Commission definitions and surgical
treatment may still lead to a cure rate of over 38 percent. However, the majority of
squamous cell carcinomas found in the clinical phase are at higher stage.
Adenocarcinoma
Unlike squamous cell carcinoma in which a combination of X-rays and sputum
cytology are useful for the early detection of the lesion, adenocarcinomas are found
in the periphery of the lung where they are not likely to shed malignant cells into the
sputum, and therefore are detected on X-ray. Mass X-ray screening has not been
very sucessful. The Philadelphia Lung Cancer Detection Program, using small
films, was unable to demonstrate an improvement in survival in their patients
detected by screen as opposed to those who presented with lung cancer [17]. Newer
screening methods have been tried and have at least yielded peripheral adenocar-
cinomas which are at a lower stage for treatment.
RESULTS OF SCREENING STUDIES
Baker and his associates [18] reported the surgical experience in treating the pa-
tients found in a screening program for over 10,000 men-half of whom had chest
X-rays and half of whom had chest X-rays and sputum cytologic studies. Thirty-
nine patients underwent resection for cure, an overall resectability rate of 55 per-
cent. Five patients had Stage 0 disease clinically and are well after a median followup
period of 36 months. Twenty-six patients had Stage I disease pathologically.
Seventy-seven percent of them are free of disease after a median followup period of
36 months. The other patients have developed second primary tumors. Three of
seven patients with Stage II disease have survived for 40 to 50 months. Only two of
17 patients with Stage III disease have survived. All nine patients with small cell car-
cinoma are dead after a median interval of eight months. The results indicate that a
screening process such as this will increase the proportion ofpatients who are at low
stage who have a better prognosis.
Melamed and his associates [5] have reported a similar experience from a similar
screening program. Forty percent of the patients detected had Stage I disease and 87
percent of these patients were alive at the time ofthe report. Only two of the 62 pa-
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tients with Stage I bronchogenic carcinoma who were treated by resection had died
of lung cancer. These authors estimate that the probability of survival for true Stage
I lung cancer is better than 90 percent at five years.
Taylor et al. [19] report a parallel study being carried out at the Mayo Clinic. They
too find that the screened group contains approximately 50 percent of cases which
are localized and low stage as determined pathologically after pulmonary resection.
Only 21 percent of the control cases fall into this favorable category.
All three of these studies have been undertaken in an effort to determine the
feasibility of screening to detect cancer of the lung at a curable stage. None of these
studies has yet been able to demonstrate a difference in the overall survival rate be-
tween screened and control groups. In part, this may be due to the fact that the
followup period is not sufficiently long at this time. Only time will tell whether a true
reduction in mortality consistent with that predicted by the detection of low-stage
disease cases can be achieved or whether the disease has only been detected earlier in
a course which is unaltered.
Another major concern regarding screening for lung cancer is the economic
feasibility of such a program. Chest X-rays and sputum cytologies are relatively ex-
pensive procedures when compared with a Pap smear or a stool analysis for occult
blood. Obviously, there is a real need to identify a high-risk group of patients who
should be subjected to this costly screening process and to lower its cost. Major ef-
forts have been made in both areas, but there is nothing which appears ready for
clinical application at this time.
In summary, much has been learned about the natural history of lung cancer. All
this information suggests that the therapeutic modalities which are currently
available can be very effective when used at an early stage of the disease. They also
show the ineffectiveness of these techniques when used in late-stage disease. Unfor-
tunately, over 80 percent of lung cancers present at an advanced stage. In the
absence of an effective preventive program, screening to detect early-stage lung
cancer appears to offer the only hope for improved survival from this disease. The
very real needs at this time are for refinement in the identification of a truly high-
risk group, and for more economical ways of screening.
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